📣 VC round data is live. Check it out!
- Public Comps
- Stryker
Stryker Valuation Multiples
Discover revenue and EBITDA valuation multiples for Stryker and similar public comparables like Danaher, Medtronic, Boston Scientific, Abbott and more.
Stryker Overview
About Stryker
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
Founded
1946
HQ

Employees
56.0K
Website
Financials (LTM)
EV
$125B
Valuation Multiples
Start free trialStryker Financials
Stryker reported last 12-month revenue of $26B and EBITDA of $7B.
In the same LTM period, Stryker generated $17B in gross profit, $7B in EBITDA, and $5B in net income.
Revenue (LTM)
Stryker P&L
In the most recent fiscal year, Stryker reported revenue of $25B and EBITDA of $6B.
Stryker is profitable as of last fiscal year, with gross margin of 64%, EBITDA margin of 25%, and net margin of 13%.
Financial data powered by Morningstar, Inc.
Stryker Stock Performance
Stryker has current market cap of $113B, and enterprise value of $125B.
Market Cap Evolution
Stryker's stock price is $295.25.
Stryker share price decreased by 6.3% in the last 30 days, and by 22.8% in the last year.
Stryker has an EPS (earnings per share) of $8.48.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $125B | $113B | 1.5% | -6.3% | -23.8% | -22.8% | $8.48 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialStryker Valuation Multiples
Stryker trades at 4.8x EV/Revenue multiple, and 16.9x EV/EBITDA.
EV / Revenue (LTM)
Stryker Financial Valuation Multiples
As of May 6, 2026, Stryker has market cap of $113B and EV of $125B.
Stryker has a P/E ratio of 20.7x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Stryker Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Stryker Margins & Growth Rates
In the most recent fiscal year, Stryker reported gross margin of 64%, EBITDA margin of 25%, and net margin of 13%.
Stryker Margins
Stryker Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Stryker Operational KPIs
Stryker's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Stryker Competitors
Stryker competitors include Danaher, Medtronic, Boston Scientific, Abbott, Intuitive Surgical, Thermo Fisher Scientific, Edwards Lifesciences, Siemens Healthineers, IDEXX Laboratories and Alcon.
Most Stryker public comparables operate across Autonomous AI & Robotics, Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 5.6x | 5.5x | 19.6x | 17.4x | |||
| 3.6x | 3.3x | 13.0x | 11.8x | |||
| 4.6x | 4.5x | 18.2x | 14.4x | |||
| 4.0x | 3.8x | 14.8x | 14.5x | |||
| 15.4x | 14.6x | 35.6x | 33.3x | |||
| 4.8x | 4.7x | 18.5x | 18.5x | |||
| 7.3x | 7.0x | 30.5x | 23.1x | |||
| 1.6x | 1.6x | 8.0x | 7.8x | |||
This data is available for Pro users. Sign up to see all Stryker competitors and their valuation data. Start Free Trial | ||||||
Stryker M&A Activity
Stryker has acquired 40 companies to date.
Last acquisition by Stryker was on January 6th 2025. Stryker acquired Inari Medical for $5B (EV/Revenue multiple of ).
Latest Acquisitions by Stryker
| Description | Inari Medical is an Irvine-based medical device company specializing in catheter-directed thrombectomy for venous thromboembolism. Its FDA-cleared FlowTriever system treats pulmonary embolism by aspirating large clots from pulmonary arteries without thrombolytics. The ClotTriever device addresses deep vein thrombosis in iliofemoral veins. Launched commercially in 2018 and 2019 respectively, these tools feature large-bore sheaths and torqueable catheters used in over 50,000 procedures annually across US hospitals. | NICO Corporation is an Indianapolis-headquartered designer and marketer of minimally invasive medical devices for neurosurgery, skull base surgery, and spinal procedures. The company produces the NICO Myriad disposable resection device, BrainPath approach system, and Apollo wand for precise tumor removal with minimal tissue damage. NICO serves neurosurgeons in the United States and internationally. | Vertos Medical is an Aliso Viejo, California-headquartered medical device company founded in 2005, acquired by Stryker in 2019. It commercializes the mild procedure using the MILD device for percutaneous lumbar decompression in lumbar spinal stenosis patients. The minimally invasive system removes hypertrophic ligamentum flavum tissue through a small trocar, treating central and lateral stenosis in outpatient settings across U.S. ambulatory surgery centers. | Care.ai is an Orlando-headquartered AI platform launched in 2018 for ambient monitoring in healthcare facilities across the United States. Powered by edge sensors, it analyzes clinical workflows in real-time to predict risks, optimize staffing, and ensure compliance. The system delivers behavior insights for hospitals, improving patient safety and provider efficiency. | |
| HQ Country | |||||
| HQ City | Los Angeles, CA | Indianapolis, IN | Los Angeles, CA | Orlando, FL | |
| Deal Date | 6 Jan 2025 | 20 Sep 2024 | 22 Aug 2024 | 12 Aug 2024 | |
| Valuation | $5B | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Stryker acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Stryker
| When was Stryker founded? | Stryker was founded in 1946. |
| Where is Stryker headquartered? | Stryker is headquartered in United States. |
| How many employees does Stryker have? | As of today, Stryker has over 56K employees. |
| Who is the CEO of Stryker? | Stryker's CEO is Kevin A. Lobo. |
| Is Stryker publicly listed? | Yes, Stryker is a public company listed on NYSE. |
| What is the stock symbol of Stryker? | Stryker trades under SYK ticker. |
| When did Stryker go public? | Stryker went public in 1979. |
| Who are competitors of Stryker? | Stryker main competitors include Danaher, Medtronic, Boston Scientific, Abbott, Intuitive Surgical, Thermo Fisher Scientific, Edwards Lifesciences, Siemens Healthineers, IDEXX Laboratories, Alcon. |
| What is the current market cap of Stryker? | Stryker's current market cap is $113B. |
| What is the current revenue of Stryker? | Stryker's last 12 months revenue is $26B. |
| What is the current revenue growth of Stryker? | Stryker revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Stryker? | Current revenue multiple of Stryker is 4.8x. |
| Is Stryker profitable? | Yes, Stryker is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Stryker? | Stryker's last 12 months EBITDA is $7B. |
| What is Stryker's EBITDA margin? | Stryker's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Stryker? | Current EBITDA multiple of Stryker is 16.9x. |
| What is the current FCF of Stryker? | Stryker's last 12 months FCF is $4B. |
| What is Stryker's FCF margin? | Stryker's last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of Stryker? | Current FCF multiple of Stryker is 33.8x. |
| How many companies Stryker has acquired to date? | As of May 2026, Stryker has acquired 40 companies. |
| What was the largest acquisition by Stryker? | $5B acquisition of Wright Medical Group on 4th November 2019 was the largest M&A Stryker has done to date. |
| What companies Stryker acquired? | Stryker acquired Wright Medical Group, Inari Medical, Sage Products, Vocera Communications, K2M, Physio-Control, Molli, Novadaq Technologies, Entellus Medical, Cerus Endovascular, and 30 other companies. |
| In how many companies Stryker has invested to date? | Stryker hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Stryker
Lists including Stryker
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
